Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. 29477-83-6
2. Lycoricidinol
3. Lycoricidin-a
4. Narciclasina
5. Lycorcidinol
6. Nacriclasine
7. Nsc266535
8. 3,4,4a,5-tetrahydro-2,3,4,7-tetrahydroxy-(1,3)dioxolo(4,5-j)phenanthridin-6(2h)-one
9. Chembl98745
10. (2s,3r,4s,4ar)-2,3,4,7-tetrahydroxy-3,4,4a,5-tetrahydro[1,3]dioxolo[4,5-j]phenanthridin-6(2h)-one
11. Chebi:70169
12. (2s,3r,4s,4ar)-2,3,4,7-tetrahydroxy-3,4,4a,5-tetrahydro-2h-[1,3]dioxolo[4,5-j]phenanthridin-6-one
13. Nsc 266535
14. Brn 1087400
15. (2s,3r,4s,4ar)-2,3,4,7-tetrahydroxy-3,4,4a,5-tetrahydro-[1,3]dioxolo[4,5-j]phenanthridin-6(2h)-one
16. (2s,3r,4s,4ar)-3,4,4a,5-tetrahydro-2,3,4,7-tetrahydroxy-(1,3)dioxolo(4,5-j)phenanthridin-6(2h)-one
17. Mls002703039
18. Mfcd01729949
19. Schembl625165
20. Cid_619061
21. Dtxsid70183677
22. Narciclasine, >=98% (hplc)
23. Zinc4097652
24. Bdbm50293603
25. Akos024457767
26. Cs-1051
27. Nsc-266535
28. (1,3)dioxolo(4,5-j)phenanthridin-6(2h)-one, 3,4,4a,5-tetrahydro-2,3,4,7-tetrahydroxy-, (2s-(2-alpha,3-beta,4-beta,4a-beta))-
29. Bp-25400
30. Hy-16563
31. Nci60_002146
32. C08533
33. J-017538
34. Brd-k06792661-001-01-9
35. Q18379239
36. [1,3]dioxolo[4,5-j]phenanthridin-6(2h)-one, 3,4,4a,5-tetrahydro-2,3,4,7-tetrahydroxy-, (2s,3r,4s,4ar)
37. [1,3]dioxolo[4,5-j]phenanthridin-6(2h)-one, 3,4,4a,5-tetrahydro-2,3,4,7-tetrahydroxy-, (2s,3r,4s,4ar)-
38. [1,5-j]phenanthridin-6(2h)-one, 3,4,4a,5-tetrahydro-2,3,4,7-tetrahydroxy-, [2s-(2.alpha.,3.beta.,4.beta.,4a.beta.)]-
39. 3kf
| Molecular Weight | 307.25 g/mol |
|---|---|
| Molecular Formula | C14H13NO7 |
| XLogP3 | -1.2 |
| Hydrogen Bond Donor Count | 5 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 0 |
| Exact Mass | 307.06920175 g/mol |
| Monoisotopic Mass | 307.06920175 g/mol |
| Topological Polar Surface Area | 129 Ų |
| Heavy Atom Count | 22 |
| Formal Charge | 0 |
| Complexity | 523 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 4 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
58
PharmaCompass offers a list of Narciclasine API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Narciclasine manufacturer or Narciclasine supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Narciclasine manufacturer or Narciclasine supplier.
PharmaCompass also assists you with knowing the Narciclasine API Price utilized in the formulation of products. Narciclasine API Price is not always fixed or binding as the Narciclasine Price is obtained through a variety of data sources. The Narciclasine Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Narciclasine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Narciclasine, including repackagers and relabelers. The FDA regulates Narciclasine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Narciclasine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Narciclasine supplier is an individual or a company that provides Narciclasine active pharmaceutical ingredient (API) or Narciclasine finished formulations upon request. The Narciclasine suppliers may include Narciclasine API manufacturers, exporters, distributors and traders.
Narciclasine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Narciclasine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Narciclasine GMP manufacturer or Narciclasine GMP API supplier for your needs.
A Narciclasine CoA (Certificate of Analysis) is a formal document that attests to Narciclasine's compliance with Narciclasine specifications and serves as a tool for batch-level quality control.
Narciclasine CoA mostly includes findings from lab analyses of a specific batch. For each Narciclasine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Narciclasine may be tested according to a variety of international standards, such as European Pharmacopoeia (Narciclasine EP), Narciclasine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Narciclasine USP).
